Table 4.

Percentage of responders in the clinical evaluation of cefditoren efficacy in clinical trials. Published data

	References	Cefditoren 200 mg bid		Cefditoren 400 mg bid		Comparatorsa
		EOTb	EFc	EOTb	EFc	EOTb	EFc
Pharyngotonsillitis	90-92	93.4 – 98.6	88.9–99.2	–	–	88.6–97.1	84.4–100
Rhinosinusitis	90,93	81.3–95.2	63.6–91.0	76.5–83.1	70.2–71.9	75.5–97.7	66.2–95.1
AECBd	89,94–97	80–88.8	79.7–83.0	84.4–95.5	78.1–85.6	75.0–98.9	79.8–85.7
CAPe	89,98,99	87.2 – 91.8	88.4–87.8	89.2–90.1	83.7–87.2	90.3–92.2	87.8–93.8

^aPenicillin V or VK (90–92) for pharyngotonsillitis, amoxicillin/clavulanic acid (90,93) or cefuroxime (90) for rhinosinusitis, cefuroxime (89,94,96) or clarithromycin (89,95) for AECB, and amoxicillin/clavulanic acid (89,98), and cefpodoxime (89,99) for CAP

^bEOT = End of Treatment

^cEF = End of Follow up

^dAECB = Acute exacerbation of chronic bronchitis

^eCAP = Community-acquired pneumonia